FHTX vs IDYA
FHTX: Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression. IDYA: IDEAYA Biosciences is a clinical-stage precision medicine company focused on discovering and developing targeted synthetic lethality therapies for oncology.
Side-by-side fundamentals
| Metric | FHTX | IDYA | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $7.07 | $39.67 | |
| Market cap as of 2026-08-24 | $420M | $3.8B | |
| Net margin as of 2026-08-24 | -175.8% | -74.8% | IDYA higher |
| Operating margin as of 2026-08-24 | -198.0% | -92.7% | IDYA higher |
| ROE as of 2026-08-24 | -301.6% | -16.5% | IDYA higher |
| ROA as of 2026-08-24 | -31.2% | -15.1% | IDYA higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-24 | +52.0% | +3118.1% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +17.1% | +62.5% | IDYA higher |
| Beta as of 2026-08-24 | 2.97 | -0.06 | |
| 1-year return as of 2026-08-21 close | +40.3% | +61.1% | IDYA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.